Lisinopril
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| N2-[(1S)-1-karboksi-3-fenilpropil]-L-lizil-L-prolin | |||
| Klinički podaci | |||
| Robne marke | Prinivil, Tensopril, Zestril, Hipril | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a692051 | ||
| Identifikatori | |||
| CAS broj | 83915-83-7 | ||
| ATC kod | C09AA03 | ||
| PubChem[1][2] | 5362119 | ||
| DrugBank | APRD00560 | ||
| ChemSpider[3] | 4514933 | ||
| UNII | 7Q3P4BS2FD 
| ||
| KEGG[4] | D00362
| ||
| ChEBI | CHEBI:43755
| ||
| ChEMBL[5] | CHEMBL1237
| ||
| Hemijski podaci | |||
| Formula | C21H31N3O5 | ||
| Mol. masa | 405,488 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Sinonimi | (2S)-1-[(2S)-6-amino-2[(1S)-1-karboksi-3-fenilpropil]amino}heksanoil]pirolidin-2-karboksilna kiselina | ||
| Farmakokinetički podaci | |||
| Bioraspoloživost | oko 25% | ||
| Vezivanje za proteine plazme | 0 | ||
| Metabolizam | None | ||
| Poluvreme eliminacije | 12 sata | ||
| Izlučivanje | Eliminiše se nepromenje u urinu | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | ℞ Prescription only | ||
| Način primene | Oralno | ||
Lisinopril je lek klase inhibitora angiotenzin konvertujućeg enzima (ACE). On se prvenstveno koristi u tretmanu hipertenzije, zatajenja srca, i srčanog udara, kao i za sprečavanje renalnih i retinalnih komplikacija uzrokovanih dijabetesom. Njegove indikacije, kontraindikacije i nuspojave su tipične za sve ACE inhibitore.
Istorijski, lisinopril je bio treći ACE inhibitor (nakon kaptoprila i enalaprila) i uveden je u upotrebu tokm ranih 1990-tih.[6]
Osobine[uredi | uredi kod]
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 7 |
| Broj donora vodonika | 4 |
| Broj rotacionih veza | 12 |
| Particioni koeficijent[7] (ALogP) | -3,7 |
| Rastvorljivost[8] (logS, log(mol/L)) | -4,2 |
| Polarna površina[9] (PSA, Å2) | 132,9 |
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Patchett A, Harris E, Tristram E, Wyvratt M, Wu M, Taub D, Peterson E, Ikeler T, ten Broeke J, Payne L, Ondeyka D, Thorsett E, Greenlee W, Lohr N, Hoffsommer R, Joshua H, Ruyle W, Rothrock J, Aster S, Maycock A, Robinson F, Hirschmann R, Sweet C, Ulm E, Gross D, Vassil T, Stone C (1980). „A new class of angiotensin-converting enzyme inhibitors”. Nature 288 (5788): 280–3. DOI:10.1038/288280a0. PMID 6253826.
- ↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o.
- ↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573.
- ↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286.
Literatura[uredi | uredi kod]
- Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P (November 1998). „Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients”. Br J Clin Pharmacol 46 (5): 467–71. DOI:10.1046/j.1365-2125.1998.00811.x. PMC 1873694. PMID 9833600.
- Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR (1985). „Once-daily lisinopril in hypertensive patients: Effect on blood pressure and the renin-angiotensin system”. Curr Therap Res 37: 342–51.